তেজৰ কেন্সাৰ
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
ক’ত যাব
ভাৰতৰ 1 খন হস্পিতালত এই trial-ৰ বাবে ৰোগী ভৰ্তি কৰা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety. The main questions it aims to answer are - 1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage? 2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml? 3. Does leflunomide prevent the need to start pre-emptive therapy for …
স্পন্সৰ: টাটা মেম'ৰিয়েল চেণ্টাৰ
ClinicalTrials.gov ত NCT07709013
ৰেজিষ্ট্ৰীত অন্তিমবাৰ আপডেট কৰা হৈছে 16 Jul 2026 · আমাৰ দ্বাৰা পঢ়া হৈছে 20 Oct 2026